Kymera Therapeutics (NASDAQ:KYMR) COO Sells $7,063,662.50 in Stock

Key Points

• COO Jeremy Chadwick sold 91,250 shares of Kymera on March 23 at an average price of $77.41, generating $7,063,662.50; the sale, disclosed in an SEC filing, cut his direct stake to 61,202 shares (a 59.85% reduction) valued at about $4.74M.
• Kymera missed quarterly expectations, reporting EPS of ($0.97) vs. consensus ($0.77) and revenue of $2.87M vs. $14.8M, with revenue down 60.8% year-over-year and negative margins; the stock recently traded near $78.93 with a market cap of $6.44B and a 12‑month range of $19.44–$103.00.
• Analysts remain largely bullish, with multiple firms raising price targets and the consensus rating at "Moderate Buy" and an average target around $118.90.

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) COO Jeremy Chadwick sold 91,250 shares of Kymera Therapeutics stock in a transaction on Monday, March 23rd. The stock was sold at an average price of $77.41, for a total transaction of $7,063,662.50. Following the transaction, the chief operating officer directly owned 61,202 shares in the company, valued at $4,737,646.82. This represents a 59.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Kymera Therapeutics Price Performance

Shares of KYMR stock traded up $4.51 on Wednesday, hitting $78.93. The stock had a trading volume of 934,950 shares, compared to its average volume of 769,289. The business has a 50 day moving average of $79.80 and a 200 day moving average of $70.30. Kymera Therapeutics, Inc. has a 12-month low of $19.44 and a 12-month high of $103.00. The stock has a market cap of $6.44 billion, a price-to-earnings ratio of -21.45 and a beta of 2.20.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($0.20). The firm had revenue of $2.87 million for the quarter, compared to analysts' expectations of $14.80 million. Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The firm's revenue for the quarter was down 60.8% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.88) earnings per share. As a group, research analysts expect that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kymera Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. boosted its position in Kymera Therapeutics by 506.6% during the second quarter. PNC Financial Services Group Inc. now owns 922 shares of the company's stock worth $40,000 after purchasing an additional 770 shares during the period. Smartleaf Asset Management LLC raised its position in shares of Kymera Therapeutics by 382.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company's stock valued at $42,000 after purchasing an additional 424 shares during the period. Larson Financial Group LLC boosted its holdings in Kymera Therapeutics by 81.5% in the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company's stock worth $44,000 after buying an additional 349 shares during the period. Osaic Holdings Inc. boosted its holdings in Kymera Therapeutics by 18,050.0% in the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company's stock worth $48,000 after buying an additional 1,083 shares during the period. Finally, Bessemer Group Inc. grew its stake in Kymera Therapeutics by 652.0% in the 3rd quarter. Bessemer Group Inc. now owns 940 shares of the company's stock valued at $53,000 after buying an additional 815 shares in the last quarter.

Analyst Upgrades and Downgrades

KYMR has been the subject of several recent analyst reports. Leerink Partners upped their target price on Kymera Therapeutics from $70.00 to $118.00 and gave the company an "outperform" rating in a report on Monday, December 8th. Stephens boosted their price objective on Kymera Therapeutics from $95.00 to $100.00 and gave the stock an "overweight" rating in a research report on Monday, March 2nd. Bank of America upped their price objective on Kymera Therapeutics from $71.00 to $112.00 and gave the company a "buy" rating in a research note on Tuesday, December 9th. Royal Bank Of Canada reiterated an "outperform" rating and set a $108.00 target price on shares of Kymera Therapeutics in a research note on Thursday, February 26th. Finally, Jefferies Financial Group started coverage on shares of Kymera Therapeutics in a research report on Monday, March 16th. They set a "buy" rating and a $110.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $118.90.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company's pipeline emphasizes immunology and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.